{
  "_id": "NCT00297271",
  "title": "Prospective Research in Memory Clinics (PRIME)",
  "text": "Summary: The purpose of the PRIME Study is to examine the current management and outcomes of patients with mild cognitive impairment or dementia. Approximately 4500 patients will be enrolled in this disease registry across 12 sites in Australia. Clinical, treatment, health status and economic data will be acquired over 3 years. The study will identify the relationships among demographic variables, prognostic features, geographic setting, treatment options and clinical, economic and health status (activities of daily living and caregiver impact) outcomes.\nInclusion criteria: inclusion criteria: \n\n Diagnosis of dementia under the DSM-IV criteria, or of Mild Cognitive Impairment, using the Peterson Criteria \n\n Living in the community (home, apartment or collective housing with nursing care available for less than 40 hours per week) \n\n Patient able to provide written informed consent, or provision of written informed consent by a legal guardian/proxy \n\n Availability of a caregiver willing to provide consent for required components of the study \n\n Fluent in English \n\n May be participating in a Phase IV or other post-marketing follow up study of an approved product for treatment of dementia \n\n \nExclusion criteria: : \n\n No concomitant life-threatening illness (a condition which is likely to interfere with the patient's ability to complete the study) \n\n Not unwilling or unable to complete the study \n\n Not concurrently participating in a clinical trial of an investigational drug (phase I, II or III) \n\n Unwillingness of patient or legal guardian / proxy to provide written informed consent \n\n Unwillingness of caregiver to provide written informed consent \n\n For patients with diagnosis of mild cognitive impairment: current or previous treatment with any cholinesterase or memantine",
  "metadata": {
    "brief_title": "Prospective Research in Memory Clinics (PRIME)",
    "phase": "",
    "drugs": "['Current treatment practice of each participating physician']",
    "drugs_list": [
      "Current treatment practice of each participating physician"
    ],
    "diseases": "['Dementia', 'Mild Cognitive Impairment']",
    "diseases_list": [
      "Dementia",
      "Mild Cognitive Impairment"
    ],
    "enrollment": "970.0",
    "inclusion_criteria": "inclusion criteria: \n\n Diagnosis of dementia under the DSM-IV criteria, or of Mild Cognitive Impairment, using the Peterson Criteria \n\n Living in the community (home, apartment or collective housing with nursing care available for less than 40 hours per week) \n\n Patient able to provide written informed consent, or provision of written informed consent by a legal guardian/proxy \n\n Availability of a caregiver willing to provide consent for required components of the study \n\n Fluent in English \n\n May be participating in a Phase IV or other post-marketing follow up study of an approved product for treatment of dementia \n\n ",
    "exclusion_criteria": ": \n\n No concomitant life-threatening illness (a condition which is likely to interfere with the patient's ability to complete the study) \n\n Not unwilling or unable to complete the study \n\n Not concurrently participating in a clinical trial of an investigational drug (phase I, II or III) \n\n Unwillingness of patient or legal guardian / proxy to provide written informed consent \n\n Unwillingness of caregiver to provide written informed consent \n\n For patients with diagnosis of mild cognitive impairment: current or previous treatment with any cholinesterase or memantine",
    "brief_summary": "The purpose of the PRIME Study is to examine the current management and outcomes of patients with mild cognitive impairment or dementia. Approximately 4500 patients will be enrolled in this disease registry across 12 sites in Australia. Clinical, treatment, health status and economic data will be acquired over 3 years. The study will identify the relationships among demographic variables, prognostic features, geographic setting, treatment options and clinical, economic and health status (activities of daily living and caregiver impact) outcomes."
  }
}